Author: Jennifer Levy

Pre-registration is now open for the LGMD EL-PFDD Meeting with FDA and other stakeholders

PRE-REGISTER NOW FOR THE LGMD EXTERNALLY-LED PATIENT-FOCUSED DRUG DEVELOPMENT MEETING TO BE HELD ON FRIDAY, SEPTEMBER 23. This no-cost, public virtual meeting is open to those living with LGMD2A, their families and caregivers, physicians, clinicians, industry/pharma representatives, academic researchers, FDA

Limb-girdle muscular dystrophy coalition to host externally-led patient focused drug development meeting

C3 is excited to announce that we’ve teamed up with the LGMD2D Foundation, the Kurt+Peter Foundation, CureLGMD2I, the McColl-Lockwood Laboratory for Muscular Dystrophy Research, and the Speak Foundation to host an Externally-Led Patient Focused Drug Development (EL-PFDD) meeting with the

It’s Official: The LGMD community celebrates adoption of ICD-10 diagnostic codes for LGMD

After a two year campaign, those with LGMD will now have a diagnostic code that matches their diagnosis! C3 is proud to have played a role in this victory alongside our friends and advocacy partners, including the Muscular Dystrophy Association,

C3 funds development of new LGMD2A/R1 disease model for preclinical testing

Coalition to Cure Calpain 3 (C3) is pleased to announce the funding of a new research award to Dr. Pia Elustondo of AGADA Biosciences. This project will characterize a novel LGMD2A/R1 disease model and utilize this model to test several

C3 awards grant to University of Florida researchers to investigate calcium handling in LGMD2A/R1

Coalition to Cure Calpain 3 (C3) is driving LGMD2A/R1 research by awarding a new grant to Dr. Elisabeth Barton and Dr. Lan Wei-LaPierre of the University of Florida. The project is titled “Strategies to improve calcium handling in LGMD2A/R1.” LGMD2A/R1

LGMD diagnostic codes proposed for final implementation

BIG NEWS! New diagnostic codes for those living with LGMD that match their diagnosis are likely on their way! Coalition to Cure Calpain 3 has been working with Muscular Dystrophy Association and other LGMD foundations, patients, and expert physicians to

Do you have questions about LGMD2A/R1?

Coalition to Cure Calpain 3 has answers! Click here to read our recently updated Frequently Asked Questions (FAQs) for patients and families.

Sarepta Therapeutics Q1 Update on LGMD Programs

Sarepta Therapeutics recently published a Community Letter to share updates on their limb-girdle muscular dystrophy gene therapy programs. Click here to access the letter on Sarepta’s website.

Daniel Ferguson LGMD Foundation Launches

C3 is pleased to share the launch of an Australian-based organization, the Daniel Ferguson LGMD Foundation. This registered charity aims to improve the lives of those living with LGMD2A/R1 by improving awareness, increasing genetic testing, and enabling those living with

Join Coalition to Cure Calpain 3 in celebrating Rare Disease Day!

Rare Disease Day takes place on the last day of February every year, with the goal of raising awareness about rare diseases and their impact on patients’ lives. Over 300 million people are living with one or more of over